• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $TXG

    10x Genomics Inc.

    Subscribe to $TXG
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

    IPO Year: 2019

    Exchange: NASDAQ

    Website: 10xgenomics.com

    Peers

    $ILMN

    Recent Analyst Ratings for 10x Genomics Inc.

    DatePrice TargetRatingAnalyst
    2/13/2025$25.00 → $12.00Outperform → Market Perform
    Leerink Partners
    9/3/2024$35.00Outperform
    Leerink Partners
    7/22/2024$24.00Hold → Buy
    Jefferies
    7/18/2024$40.00 → $20.00Overweight → Neutral
    JP Morgan
    7/10/2024$55.00 → $25.00Buy → Hold
    Deutsche Bank
    6/27/2024Outperform → Peer Perform
    Wolfe Research
    6/25/2024Buy → Neutral
    Guggenheim
    6/3/2024$24.00Hold
    Jefferies
    5/1/2024$57.00 → $32.00Buy → Hold
    TD Cowen
    12/14/2023$60.00Buy
    Guggenheim
    See more ratings

    10x Genomics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • 10x Genomics Announces Senior Leadership Changes

      PLEASANTON, Calif., Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today several changes to its executive team. Mennah Moustafa has been named Chief Commercial Officer, effective August 1. In this role, Moustafa will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions.Justin McAnear, Chief Financial Officer, will resign from the company effective August 30, to join a private company.Adam Taich has been appointed Chief Financial Officer

      8/8/24 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Fanatics Announces Appointment of Lydia Jett and Jonathan Mildenhall to Board of Directors

      Jett and Mildenhall will bring transformative vision and wide-ranging expertise to the fast-growing digital sports platform Separately, Fanatics releases its first environmental, social and governance (ESG) report Fanatics, a leading global digital sports platform, today announced the appointment of preeminent fintech, e-commerce and marketing executives Lydia Jett and Jonathan Mildenhall to its board of directors. Jett, Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA), and Mildenhall, co-founder and Executive Chairman of TwentyFirstCenturyBrand and former CMO of Airbnb, bring decades of experience advising an

      5/5/22 8:30:00 AM ET
      $CPNG
      $GH
      $OZON
      $TXG
      Catalog/Specialty Distribution
      Consumer Discretionary
      Medical Specialities
      Health Care
    • ReCode Therapeutics Appoints Shehnaaz Suliman, M.D., MBA, M.Phil., as Chief Executive Officer

      Dr. Suliman brings over 25 years of drug development, deal-making and company building expertise as ReCode continues advancing its pipeline of novel genetic medicines using its powerful selective organ targeting (SORT) LNP delivery platform ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as chief executive officer and as a member of the board of directors effective today. Former CEO, David Lockhart, Ph.D., will transition to the role of chief scientific officer and will remain president and a member of the boar

      1/10/22 8:00:00 AM ET
      $RARE
      $TXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    10x Genomics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Saxonov Serge was granted 171,428 shares, increasing direct ownership by 19% to 1,092,968 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      3/19/25 5:35:44 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Officer Hindson Benjamin J. was granted 120,535 shares, increasing direct ownership by 36% to 455,859 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      3/19/25 5:35:12 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Financial Officer Taich Adam was granted 335,632 shares (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      3/19/25 5:34:38 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Executive Officer Saxonov Serge sold $84,393 worth of shares (7,942 units at $10.63) and exercised 50,000 shares at a strike of $1.20, increasing direct ownership by 5% to 921,540 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      3/4/25 6:50:19 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Officer Hindson Benjamin J. sold $50,603 worth of shares (4,573 units at $11.07), decreasing direct ownership by 1% to 335,324 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      2/26/25 5:43:37 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Executive Officer Saxonov Serge sold $56,346 worth of shares (5,092 units at $11.07), decreasing direct ownership by 0.58% to 879,482 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      2/26/25 5:42:46 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Mateo Alan bought $445,572 worth of shares (40,000 units at $11.14), increasing direct ownership by 184% to 61,691 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      2/25/25 5:22:04 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Executive Officer Saxonov Serge exercised 12,000 shares at a strike of $1.20, increasing direct ownership by 1% to 884,574 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      12/23/24 8:29:36 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Executive Officer Saxonov Serge gifted 1,850 shares and sold $91,612 worth of shares (6,693 units at $13.69), decreasing direct ownership by 0.97% to 872,574 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      11/25/24 4:53:14 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Officer Hindson Benjamin J. sold $79,485 worth of shares (5,807 units at $13.69), decreasing direct ownership by 2% to 339,897 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      11/25/24 4:52:29 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    10x Genomics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • 10x Genomics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded 10x Genomics from Outperform to Market Perform and set a new price target of $12.00 from $25.00 previously

      2/13/25 7:11:34 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Leerink Partners initiated coverage on 10x Genomics with a new price target

      Leerink Partners initiated coverage of 10x Genomics with a rating of Outperform and set a new price target of $35.00

      9/3/24 8:15:17 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics upgraded by Jefferies with a new price target

      Jefferies upgraded 10x Genomics from Hold to Buy and set a new price target of $24.00

      7/22/24 8:21:12 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics downgraded by JP Morgan with a new price target

      JP Morgan downgraded 10x Genomics from Overweight to Neutral and set a new price target of $20.00 from $40.00 previously

      7/18/24 8:01:25 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded 10x Genomics from Buy to Hold and set a new price target of $25.00 from $55.00 previously

      7/10/24 8:07:50 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics downgraded by Wolfe Research

      Wolfe Research downgraded 10x Genomics from Outperform to Peer Perform

      6/27/24 7:52:29 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics downgraded by Guggenheim

      Guggenheim downgraded 10x Genomics from Buy to Neutral

      6/25/24 8:03:32 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Jefferies resumed coverage on 10x Genomics with a new price target

      Jefferies resumed coverage of 10x Genomics with a rating of Hold and set a new price target of $24.00

      6/3/24 8:22:07 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics downgraded by TD Cowen with a new price target

      TD Cowen downgraded 10x Genomics from Buy to Hold and set a new price target of $32.00 from $57.00 previously

      5/1/24 8:25:25 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Guggenheim initiated coverage on 10x Genomics with a new price target

      Guggenheim initiated coverage of 10x Genomics with a rating of Buy and set a new price target of $60.00

      12/14/23 7:54:20 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    10x Genomics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 10x Genomics Reports First Quarter 2025 Financial Results

      PLEASANTON, Calif., May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025. Recent Updates Revenue was $154.9 million for the first quarter. Excluding $16.8 million related to a patent litigation settlement, revenue was $138.1 million, a 2% decrease from the corresponding period of 2024, primarily driven by a significant decrease in instrument revenue.Ended the first quarter with cash and cash equivalents and marketable securities of $426.9 million. As

      5/8/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics to Participate in the BofA Securities 2025 Healthcare Conference

      PLEASANTON, Calif., April 30, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference on Tuesday, May 13, at 11:20 a.m. Pacific Time. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event. About 10x Genomics

      4/30/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025

      PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 8, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

      4/14/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products

      10x Genomics' ATAC-Seq patents found valid and infringed PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (NASDAQ:TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, 2025, in the United States District Court for the District of Delaware, Parse agreed - a week before trial was to start - to a worldwide permanent injunction that prevents it from making, using, selling or offering for sale its planned ATAC and ATAC-Multiome Single Cell products. As part of this consent agreement, Parse admitted that 10x's ATAC-seq patents are valid, enforceable and infringed

      3/3/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis

      New single cell and spatial innovations extend 10x Genomics' technology and performanceleadership across all three platforms PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced a series of new product innovations to solidify its position as the best partner for high-performance single cell research at scale. In addition, the company unveiled a robust new product roadmap for its Visium and Xenium portfolios, extending its performance and technology leadership in the rapidly growing field of spatial biology.

      2/23/25 11:30:00 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference

      PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, at 11:10 a.m. Eastern Time. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 45 days after the event. About 10x Genomic

      2/18/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025

      PLEASANTON, Calif., Feb. 12, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided outlook for 2025. Recent Updates Revenue was $165.0 million for the fourth quarter and $610.8 million for the full year of 2024, representing 10% and 1% decreases over the corresponding periods of 2023.In collaboration with the Chan Zuckerberg Initiative (CZI) and Ultima Genomics, launched the Billion Cells Project, an effort to generate an unpre

      2/12/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chan Zuckerberg Initiative Launches Billion Cells Project with 10x Genomics and Ultima Genomics to Advance AI in Biology

      Landmark single-cell dataset of one billion cells will be used to train new AI models to advance researchers' understanding of cellular behavior and gene function REDWOOD CITY, Calif. , Feb. 6, 2025 /PRNewswire/ -- Today, the Chan Zuckerberg Initiative (CZI) launched the Billion Cells Project, an effort to generate an unprecedented one billion cell dataset to fuel rapid progress in AI model development in biology. CZI is embarking on this landmark initiative in collaboration with partners 10x Genomics, Ultima Genomics, and a group of leading researchers. Industry partners are enabling data generation at unprecedented scale by increasing access to cutting-edge technologies and lowering costs.

      2/6/25 8:30:00 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025

      PLEASANTON, Calif., Jan. 28, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Wednesday, February 12, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

      1/28/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results

      FY 2024 revenue of ~$611 million and Q4 2024 revenue of ~$165 million, representing 9% growth sequentially PLEASANTON, Calif., Jan. 12, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2024. Preliminary, Unaudited Select Fourth Quarter 2024 Financial Results Revenue of approximately $165.0 million for the three months ended December 31, 2024, representing 9% growth sequentially and a 10% decrease as compared to the corr

      1/12/25 12:00:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    10x Genomics Inc. SEC Filings

    See more
    • 10x Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

      8-K - 10x Genomics, Inc. (0001770787) (Filer)

      5/8/25 4:05:10 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.

      SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

      5/7/25 10:55:48 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.

      SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

      5/7/25 10:40:41 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.

      SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

      4/25/25 6:22:20 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEF 14A filed by 10x Genomics Inc.

      DEF 14A - 10x Genomics, Inc. (0001770787) (Filer)

      4/14/25 4:24:38 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SCHEDULE 13G filed by 10x Genomics Inc.

      SCHEDULE 13G - 10x Genomics, Inc. (0001770787) (Subject)

      4/4/25 4:00:18 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 144 filed by 10x Genomics Inc.

      144 - 10x Genomics, Inc. (0001770787) (Subject)

      2/28/25 5:03:41 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form S-8 filed by 10x Genomics Inc.

      S-8 - 10x Genomics, Inc. (0001770787) (Filer)

      2/13/25 9:23:52 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - 10x Genomics, Inc. (0001770787) (Filer)

      2/12/25 4:10:24 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - 10x Genomics, Inc. (0001770787) (Filer)

      1/13/25 8:49:43 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    10x Genomics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by 10x Genomics Inc.

      SC 13G - 10x Genomics, Inc. (0001770787) (Subject)

      11/8/24 2:46:37 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by 10x Genomics Inc.

      SC 13G - 10x Genomics, Inc. (0001770787) (Subject)

      11/5/24 6:07:26 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by 10x Genomics Inc.

      SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

      10/4/24 2:14:32 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by 10x Genomics Inc.

      SC 13G - 10x Genomics, Inc. (0001770787) (Subject)

      8/12/24 11:16:15 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by 10x Genomics Inc. (Amendment)

      SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

      6/7/24 9:55:19 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by 10x Genomics Inc. (Amendment)

      SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

      2/13/24 4:55:54 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by 10x Genomics Inc. (Amendment)

      SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

      2/9/24 8:35:54 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by 10x Genomics Inc. (Amendment)

      SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

      1/31/24 2:08:26 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by 10x Genomics Inc. (Amendment)

      SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

      1/29/24 11:43:15 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by 10x Genomics Inc. (Amendment)

      SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

      12/8/23 4:37:11 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    10x Genomics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mateo Alan bought $445,572 worth of shares (40,000 units at $11.14), increasing direct ownership by 184% to 61,691 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      2/25/25 5:22:04 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    10x Genomics Inc. Financials

    Live finance-specific insights

    See more
    • 10x Genomics Reports First Quarter 2025 Financial Results

      PLEASANTON, Calif., May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025. Recent Updates Revenue was $154.9 million for the first quarter. Excluding $16.8 million related to a patent litigation settlement, revenue was $138.1 million, a 2% decrease from the corresponding period of 2024, primarily driven by a significant decrease in instrument revenue.Ended the first quarter with cash and cash equivalents and marketable securities of $426.9 million. As

      5/8/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025

      PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 8, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

      4/14/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025

      PLEASANTON, Calif., Feb. 12, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided outlook for 2025. Recent Updates Revenue was $165.0 million for the fourth quarter and $610.8 million for the full year of 2024, representing 10% and 1% decreases over the corresponding periods of 2023.In collaboration with the Chan Zuckerberg Initiative (CZI) and Ultima Genomics, launched the Billion Cells Project, an effort to generate an unpre

      2/12/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025

      PLEASANTON, Calif., Jan. 28, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Wednesday, February 12, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

      1/28/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics Reports Third Quarter 2024 Financial Results

      PLEASANTON, Calif., Oct. 29, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Revenue was $151.7 million for the third quarter, in line with the company's preliminary announcement, a 1% decrease over the corresponding period of 2023, primarily driven by lower instrument revenue, offset by stronger contributions from consumables.Began shipping GEM-X Flex, setting a new standard for the cost per cell for researchers and enabling the

      10/29/24 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics Announces Preliminary Select Third Quarter 2024 Results

      PLEASANTON, Calif., Oct. 9, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced preliminary select results for the third quarter ended September 30, 2024. Preliminary Select Third Quarter 2024 Results Revenue of approximately $151.7 million for the third quarter ended September 30, 2024, representing an approximate 1% decrease from the corresponding prior year period.Preliminary revenue by source for the third quarter is expected to be as follows:Instruments revenue of approximately $19.1 million, representing a 46

      10/9/24 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics Reports Second Quarter 2024 Financial Results

      PLEASANTON, Calif. , Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Revenue was $153.1 million for the second quarter, a 4% increase over the corresponding period of 2023, primarily driven by stronger contributions from consumables.Began shipping Xenium Prime 5K, which measures 5,000 genes and features an enhanced chemistry to deliver excellent per-gene sensitivity, improved specificity and spatial fidelity, and integrated m

      8/8/24 4:04:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024

      PLEASANTON, Calif., July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the second quarter ended June 30, 2024 after market close on Thursday, August 8, 2024. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

      7/12/24 8:00:00 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics Reports First Quarter 2024 Financial Results

      PLEASANTON, Calif., April 30, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Revenue was $141.0 million for the first quarter, a 5% increase over the corresponding period of 2023, driven by Spatial revenue.Shipped Visium HD Spatial Gene Expression, enabling whole transcriptome spatial discovery at single cell-scale resolution.Shipped two major new Chromium products powered by GEM-X, the next generation of the company's leading singl

      4/30/24 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024

      PLEASANTON, Calif., April 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on Tuesday, April 30, 2024. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

      4/10/24 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials